Literature DB >> 19328038

Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection.

Ming Shi1, Junliang Fu, Feng Shi, Bin Zhang, Zirong Tang, Lei Jin, Zhenping Fan, Zheng Zhang, Liming Chen, Huifeng Wang, George K K Lau, Fu-Sheng Wang.   

Abstract

Adoptive immune transfer plays an important role in clearance of hepatitis B virus (HBV) in chronic hepatitis B (CHB) patients. However, it is unclear whether cytokine-induced killer (CIK) cells could suppress HBV replication in CHB patients, especially if drug resistance develops. In this study, functional CIK cells were efficiently generated from 21 CHB patients and were transfused in an autologous manner. We found that CIK cells from the CHB patients displayed substantial proliferation and function. Administration of the CIK cells closely correlated with the decrease in the serum HBV load and improvement in liver function in some patients. The virological response rate in patients with baseline serum alanine aminotransferase (ALT) levels of >40 U/L was higher than that in patients with baseline serum ALT levels of < or = 40 U/L. Moreover, patients who had HBeAg loss or showed seroconversion generally had baseline serum ALT levels of >40 U/L. No serious side effects were observed. This protocol represents an alternative immune therapeutic strategy for the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328038     DOI: 10.1016/j.clim.2009.03.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

Review 1.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

2.  High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.

Authors:  Boyang Chang; Lujun Shen; Kefeng Wang; Jietian Jin; Tao Huang; Qifeng Chen; Wang Li; Peihong Wu
Journal:  Liver Int       Date:  2018-02-13       Impact factor: 5.828

3.  Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis.

Authors:  Peijun Tang; Xingnian Chen; Junchi Xu; Yunlong Hu; Zhijian Ye; Xiafang Wang; Yumei Xiao; Xinghua Shen; Jianping Zhang; Yanjun Feng; Cuilin Shi; Xin Yu; Lixian Yi; Xinchun Chen; Binfeng Lu; Ping Xu; Zhongwen Sun; Meiying Wu
Journal:  J Immunol Res       Date:  2022-03-17       Impact factor: 4.818

4.  Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.

Authors:  Jian-Lin Chen; Xiang-Ming Lao; Xiao-Jun Lin; Li Xu; Bo-Kang Cui; Jun Wang; Guo-He Lin; Ze-Yu Shuang; Yi-Ze Mao; Xin Huang; Jing-Ping Yun; Jie-Tian Jin; Sheng-Ping Li
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

5.  Impact of Interferon-α Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Timokratis Karamitros; George Papatheodoridis; Dimitrios Paraskevis; Angelos Hatzakis; Jean L Mbisa; Urania Georgopoulou; Paul Klenerman; Gkikas Magiorkinis
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.